Vaxcyte CFO exercises 10K options, sells 10K shares
Vaxcyte, Inc. President and CFO Andrew Guggenhime reported an option exercise and related share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vaxcyte, Inc. President and CFO Andrew Guggenhime reported an option exercise and related share sales. He exercised stock options to acquire 10,000 shares of Common Stock at $5.35 per share, then sold 10,000 shares in two open-market transactions.
The sales covered 2,087 shares at a weighted-average price of about $57.76 and 7,913 shares at a weighted-average price of about $57.16, with actual prices ranging from $56.595 to $58.32, pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. Following these transactions, he holds 104,395 shares directly and 61,850 shares indirectly through ALG 2025 GRAT Holdings LLC.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($519K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
GUGGENHIME ANDREW
Role
PRESIDENT AND CFO
Sold
10,000 shs ($573K)
Approx. gross sale proceeds
$573K
Approx. exercise cost
$54K
Approx. pre-tax spread
$519K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $5.35 | $54K |
| Sale | Common Stock | 7,913 | $57.157 | $452K |
| Sale | Common Stock | 2,087 | $57.764 | $121K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 226,827 contracts (Direct);
Common Stock — 104,395 shares (Direct);
Common Stock — 61,850 shares (Indirect, See Footnote)
Footnotes (5)
- F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
- F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.61 to $58.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
- F5. Option is fully vested and exercisable.
Key Figures
Shares sold (block 1): 2,087 shares at $57.764
Shares sold (block 2): 7,913 shares at $57.157
Options exercised: 10,000 shares at $5.35
+4 more
7 metrics
Shares sold (block 1)
2,087 shares at $57.764
Open-market sale of Common Stock on July 6, 2026
Shares sold (block 2)
7,913 shares at $57.157
Open-market sale of Common Stock on July 6, 2026
Options exercised
10,000 shares at $5.35
Stock option exercise of Common Stock on July 6, 2026
Direct holdings after transactions
104,395 shares
Common Stock directly owned following reported trades
Indirect holdings via ALG 2025 GRAT Holdings LLC
61,850 shares
Common Stock held indirectly as reported in holding entry
Net shares sold
10,000 shares
Net of 10,000 shares sold versus 10,000 shares exercised
Option expiration date
May 11, 2030
Original expiration for stock option that was exercised
Key Terms
Rule 10b5-1 trading plan, weighted-average price, grantor retained annuity trust, Stock Option (right to buy), +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
grantor retained annuity trust financial
"100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee."
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Common Stock and exercise price of $5.35."
annuitant financial
"The Reporting Person is the annuitant and the trustee of the grantor retained annuity trust."
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates